transforming-growth-factor-beta and Nerve-Degeneration

Optic nerve degeneration caused by glaucoma is a leading cause of blindness worldwide. Patients affected by the normal-pressure form of glaucoma are more likely to harbor risk alleles for glaucoma-related optic nerve disease. We have performed a meta-analysis of two independent genome-wide association studies for primary open angle glaucoma (POAG) followed by a normal-pressure glaucoma (NPG, defined by intraocular pressure (IOP) less than 22 mmHg) subgroup analysis. The single-nucleotide polymorphisms that showed the most significant associations were tested for association with a second form of glaucoma, exfoliation-syndrome glaucoma. The overall meta-analysis of the GLAUGEN and NEIGHBOR dataset results (3,146 cases and 3,487 controls) identified significant associations between two loci and POAG: the CDKN2BAS region on 9p21 (rs2157719 [G], OR = 0.69 [95%CI 0.63-0.75], p = 1.86×10⁻¹⁸), and the SIX1/SIX6 region on chromosome 14q23 (rs10483727 [A], OR = 1.32 [95%CI 1.21-1.43], p = 3.87×10⁻¹¹). In sub-group analysis two loci were significantly associated with NPG: 9p21 containing the CDKN2BAS gene (rs2157719 [G], OR = 0.58 [95% CI 0.50-0.67], p = 1.17×10⁻¹²) and a probable regulatory region on 8q22 (rs284489 [G], OR = 0.62 [95% CI 0.53-0.72], p = 8.88×10⁻¹⁰). Both NPG loci were also nominally associated with a second type of glaucoma, exfoliation syndrome glaucoma (rs2157719 [G], OR = 0.59 [95% CI 0.41-0.87], p = 0.004 and rs284489 [G], OR = 0.76 [95% CI 0.54-1.06], p = 0.021), suggesting that these loci might contribute more generally to optic nerve degeneration in glaucoma. Because both loci influence transforming growth factor beta (TGF-beta) signaling, we performed a genomic pathway analysis that showed an association between the TGF-beta pathway and NPG (permuted p = 0.009). These results suggest that neuro-protective therapies targeting TGF-beta signaling could be effective for multiple forms of glaucoma.

Topics: Alleles; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; Exfoliation Syndrome; Genome-Wide Association Study; Glaucoma, Open-Angle; Homeodomain Proteins; Humans; Nerve Degeneration; Optic Nerve; Polymorphism, Single Nucleotide; RNA, Long Noncoding; RNA, Untranslated; Transforming Growth Factor beta

Alzheimer's disease (AD) is a fatal neurodegenerative disease characterized by the loss of large numbers of forebrain neurons. There are currently no effective AD treatments available and the cause of the disease is unknown in the majority of cases. Because normal neuronal maintenance and survival depends on stimulation of key signaling pathways by a number of neurotrophic factors it has been postulated that reduced signaling by or expression of these factors may promote neurodegeneration. Growing evidence suggests that the transforming growth factor-beta (TGF-beta) signaling pathway may be one such neurotrophic pathway that meets important protective and survival roles in neurons. Here I explore this evidence and discuss the pathway as a potential target for the treatment of neurodegeneration and AD.

Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Humans; Mice; Mice, Transgenic; Microglia; Nerve Degeneration; Nerve Growth Factors; Neurons; Neuroprotective Agents; Signal Transduction; Transforming Growth Factor beta

Dopaminergic neurons of the nigrostriatal system are important in the control of motor performance and degenerate in Parkinson's disease. Therefore, in order to design novel strategies for the treatment of Parkinson's disease, it is important for us to understand their development, function, trophic factor requirements, plasticity and susceptibility to toxic influences. A large and still increasing number of growth factors have been implicated in the regulation of the survival and differentiation of dopaminergic neurons. These factors may also protect against a variety of toxic influences. On the basis of their localization, putative sources and mechanisms of actions, such growth factors fall into several categories: (i) local factors within the midbrain influencing proliferation, transmitter phenotype, migration, positioning and neurite growth of stem cells and early neurons; (ii) factors acting retrogradely from the striatum, which are responsible for intrastriatal sprouting and navigation of newly arrived axons as well as life-long maintenance of the dopaminergic nigrostriatal connection; (iii) factors coming into play when the system is toxically impaired; (iv) factors directly acting on dopaminergic neurons; and (v) factors provided by cytokinestimulated astroglia, microglia and neurons affecting dopaminergic neurons anterogradely. This article reviews actions of growth factors on dopaminergic neurons in vitro and in vivo, with a focus on members of the transforming growth factor (TGF)-beta superfamily. TGF-beta s may be particularly relevant to dopaminergic neurons, since they are expressed in the nigrostriatal system from early embryonic stages to adulthood and are significantly up-regulated in response to lesions.

Topics: Animals; Dopamine Agents; Humans; Mesencephalon; Nerve Degeneration; Neurons; Parkinson Disease; Transforming Growth Factor beta

We used two methods to examine altered patterns of gene expression in rat hippocampus in response to administered glucocorticoids: analysis of RNA in vitro translation products on 2-d gels and cloning of cDNAs from a rat hippocampal library by differential hybridization (+/- CORT). We determined that two of the CORT-responsive cDNA clones encoded the 35- and 50-kd RNA translation products and identified them as GPDH and GFAP, respectively, by sequence analysis. Cloned mRNAs that increased and decreased in response to CORT were determined to be under positive and negative regulation by glucocorticoids in intact rats. Despite their similarities in glucocorticoid response characteristics, we found three subsets of hippocampal mRNA responses to CORT and shaking stress which differ in temporal and level-dependent aspects of CORT regulation. In addition, GPDH gene expression represents a glucocorticoid-dependent stress response which is rapidly increased in a dose- and stressor-dependent manner. It is a candidate for a sensitive indicator of stress responsiveness in the brain as a function of neuroendocrine activity. Mechanisms of adaptation to stress in the brain are likely to involve responses that are both mediated by glucocorticoids and opposed by them. GFAP and TGF-beta 1 mRNA responses may be examples of the latter, since they are decreased in response to glucocorticoids, are under negative regulation by glucocorticoids in intact rats, and are increased in response to brain injury and disease and during aging. If these astrocytic and microglial responses are involved in cellular defense mechanisms in the brain, then their regulation by glucocorticoids would be important in maintaining and restoring cellular homeostasis in physiological and pathophysiological states. Future studies using these sensitive probes for glucocorticoid-regulated gene expression may identify new mechanisms by which the brain coordinates acute and chronic responses to stress and disease.

Topics: Adrenal Cortex Hormones; Adrenalectomy; Aging; Animals; Cloning, Molecular; Corticosterone; Gene Expression; Glial Fibrillary Acidic Protein; Hippocampus; Humans; In Situ Hybridization; Nerve Degeneration; Protein Biosynthesis; Rats; RNA, Messenger; Stress, Physiological; Transforming Growth Factor beta

TGF-beta 1 mRNA and protein were recently found to increase in animal brains after experimental lesions that cause local deafferentation or neuron death. Elevations of TGF-beta 1 mRNA after lesions are prominent in microglia but are also observed in neurons and astrocytes. Moreover, TGF-beta 1 mRNA autoinduces its own mRNA in the brain. These responses provide models for studying the increases of TGF-beta 1 protein observed in beta A/amyloid-containing extracellular plaques of Alzheimer's disease (AD) and Down's syndrome (DS) and in brain cells of AIDS victims. Involvement of TGF-beta 1 in these human brain disorders is discussed in relation to the potent effects of TGF-beta 1 on wound healing and inflammatory responses in peripheral tissues. We hypothesize that TGF-beta 1 and possibly other TGF-beta peptides have organizing roles in responses to neurodegeneration and brain injury that are similar to those observed in non-neural tissues. Work from many laboratories has shown that activities of TGF-beta peptides on brain cells include chemotaxis, modification of extracellular matrix, and regulation of cytoskeletal gene expression and of neurotrophins. Similar activities of the TGF-beta's are well established in other tissues.

Topics: Animals; Brain Diseases; Humans; Immunity; Inflammation; Nerve Degeneration; RNA, Messenger; Transforming Growth Factor beta

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition characterized by the loss of motor neurons. We utilized single-cell transcriptomics to uncover dysfunctional pathways in degenerating motor neurons differentiated from SOD1 E100G ALS patient-derived induced pluripotent stem cells (iPSCs) and respective isogenic controls. Differential gene expression and network analysis identified activation of developmental pathways and core transcriptional factors driving the ALS motor neuron gene dysregulation. Specifically, we identified activation of SMAD2, a downstream mediator of the transforming growth factor β (TGF-β) signaling pathway as a key driver of SOD1 iPSC-derived motor neuron degeneration. Importantly, our analysis indicates that activation of TGFβ signaling may be a common mechanism shared between SOD1, FUS, C9ORF72, VCP, and sporadic ALS motor neurons. Our results demonstrate the utility of single-cell transcriptomics in mapping disease-relevant gene regulatory networks driving neurodegeneration in ALS motor neurons. We find that ALS-associated mutant SOD1 targets transcriptional networks that perturb motor neuron homeostasis.

Topics: Amyotrophic Lateral Sclerosis; Gene Expression Profiling; Gene Expression Regulation; Gene Regulatory Networks; Humans; Induced Pluripotent Stem Cells; Interneurons; Motor Neurons; Nerve Degeneration; Signal Transduction; Single-Cell Analysis; Superoxide Dismutase-1; Transforming Growth Factor beta

The purpose of this study was to explore retina-intrinsic neuroinflammatory reactions, effects on neuronal survival, relationship with classic gliosis, and possible role of the toll-like receptor 4 (TLR4). To isolate the adult retina from the systemic immune system, a previously described large animal explant culture model was used in which full-thickness porcine retinal sheets can be kept in vitro for extended time periods. Explants were kept for 5 days in vitro (DIV) and were treated with either; lipopolysaccharide (LPS), a Toll-like receptor-4 (TLR4) inhibitor (CLI-095), LPS + CLI-095, or solvent vehicle throughout the culture period after which retinal sections were examined with hematoxylin and eosin staining and extensive immunohistochemistry. In addition, culture medium from all explant groups was assayed for a panel of cytokines at 2 and 5DIV. Compared with in vivo controls, vehicle controls (CT) as well as CLI-095 explants displayed moderate reduction of total thickness and number of retinal neurons with upregulation of glial fibrillary acidic protein (GFAP) throughout the Müller cells. In contrast, LPS and LPS + CLI-095 treated counterparts showed extensive overall thinning with widespread neuronal degeneration but only minimal signs of classical Müller cell gliosis (limited upregulation of GFAP and no downregulation of glutamine synthetase (GS). These specimens also displayed a significantly increased expression of galectin-3 and TGF-beta activated kinase 1 (TAK1). Multiplex proteomic analysis of culture medium at 2DIV revealed elevated levels of IL-1β, IL-6, IL-4 and IL-12 in LPS-treated explants compared to CLI-095 and CT counterparts. LPS stimulation of the isolated adult retina results in substantial neuronal cell death despite only minimal signs of gliosis indicating a retina-intrinsic neuroinflammatory response directly related to the degenerative process. This response is characterized by early upregulation of several inflammatory related cytokines with subsequent upregulation of Galectin-3, TLR4 and TAK1. Pharmacological block of TLR4 does not attenuate neuronal loss indicating that LPS induced retinal degeneration is mediated by TLR4 independent neuroinflammatory pathways.

Topics: Animals; Cell Survival; Cells, Cultured; Cytokines; Disease Models, Animal; Galectin 3; Glial Fibrillary Acidic Protein; Gliosis; Glutamate-Ammonia Ligase; Inflammation; Lipopolysaccharides; Nerve Degeneration; Proteomics; Retinal Degeneration; Retinal Neurons; Swine; Toll-Like Receptor 4; Transforming Growth Factor beta

Complement-associated factors are implicated in pathogen presentation, neurodegeneration, and microglia resolution of tissue injury. To characterize complement activation with microglial clearance of degenerating mossy fiber boutons, hippocampal dentate granule neurons were ablated in CD-1 mice with trimethyltin (TMT; 2.2 mg/kg, i.p.). Neuronal apoptosis was accompanied by amoeboid microglia and elevations in tumor necrosis factor [Tnfa], interleukin 1β [Il1b], and Il6 mRNA and C1q protein. Inos mRNA levels were unaltered. Silver degeneration and synaptophysin staining indicated loss of synaptic innervation to CA3 pyramidal neurons. Reactive microglia with thickened bushy morphology showed co-localization of synaptophysin+ fragments. The initial response at 2 days post-TMT included transient elevations in Tnfa, Il1b, Il6, and Inos mRNA levels. A concurrent increase at 2 days was observed in arginase-1 [Arg1], Il10, transforming growth factor β1 [Tgfb1], and chitinase 3 like-3 [Ym1] mRNA levels. At 2 days, C1q protein was evident in the CA3 with elevated C1qa, C1qb, C3, Cr3a, and Cr3b mRNA levels. mRNA levels remained elevated at 5 days, returning to control by 14 days, corresponding to silver degeneration. mRNA levels for pentraxin3 (Ptx3) were elevated on day 2 and Ptx1 was not altered. Our data suggest an association between microglia reactivity, the induction of anti-inflammatory genes concurrent with pro-inflammatory genes and the expression of complement-associated factors with the degeneration of synapses following apoptotic neuronal loss.

Topics: Animals; Apoptosis; Arginase; beta-N-Acetylhexosaminidases; C-Reactive Protein; Complement System Proteins; Dentate Gyrus; Inflammation Mediators; Interleukin-10; Interleukin-1beta; Interleukin-6; Lectins; Male; Mice; Microglia; Mossy Fibers, Hippocampal; Nerve Degeneration; Nerve Tissue Proteins; Nitric Oxide Synthase Type II; Paired Box Transcription Factors; Synapses; Synaptophysin; Transforming Growth Factor beta; Trimethyltin Compounds; Tumor Necrosis Factor-alpha

Immunosuppression is a characteristic feature of Toxoplasma gondii-infected murine hosts. The present study aimed to determine the effect of the immunosuppression induced by T. gondii infection on the pathogenesis and progression of Alzheimer's disease (AD) in Tg2576 AD mice. Mice were infected with a cyst-forming strain (ME49) of T. gondii, and levels of inflammatory mediators (IFN-γ and nitric oxide), anti-inflammatory cytokines (IL-10 and TGF-β), neuronal damage, and β-amyloid plaque deposition were examined in brain tissues and/or in BV-2 microglial cells. In addition, behavioral tests, including the water maze and Y-maze tests, were performed on T. gondii-infected and uninfected Tg2576 mice. Results revealed that whereas the level of IFN-γ was unchanged, the levels of anti-inflammatory cytokines were significantly higher in T. gondii-infected mice than in uninfected mice, and in BV-2 cells treated with T. gondii lysate antigen. Furthermore, nitrite production from primary cultured brain microglial cells and BV-2 cells was reduced by the addition of T. gondii lysate antigen (TLA), and β-amyloid plaque deposition in the cortex and hippocampus of Tg2576 mouse brains was remarkably lower in T. gondii-infected AD mice than in uninfected controls. In addition, water maze and Y-maze test results revealed retarded cognitive capacities in uninfected mice as compared with infected mice. These findings demonstrate the favorable effects of the immunosuppression induced by T. gondii infection on the pathogenesis and progression of AD in Tg2576 mice.

Topics: Alzheimer Disease; Amyloid; Animals; Behavior, Animal; Brain; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Hippocampus; Interferon-gamma; Interleukin-10; Learning; Memory Disorders; Mice; Microglia; Nerve Degeneration; Nitric Oxide; Toxoplasma; Toxoplasmosis, Animal; Transforming Growth Factor beta

Glutamatergic neurotransmission has been implicated in mechanisms of alcohol-induced neurodegeneration and cognitive impairment, but the underlying mechanism remains unknown. Here, we examined whether the group II metabotropic glutamate receptor agonist LY379268 prevents neuronal death and learning deficits in a rat model of binge-like exposure to alcohol.. Following 4-day binge alcohol exposure concurrent with LY379268 or vehicle treatment, Fluoro-Jade B and transforming growth factor-beta (TGF-beta) staining were carried out, and reversal learning in the Morris water maze was assessed.. Fluoro-Jade B staining indicating neurodegeneration was most extensive in the ventral hippocampus and the entorhinal cortex (EC). LY379268 was potently neuroprotective in the EC but not in the dentate gyrus of the hippocampus. In parallel, binge alcohol exposure suppressed TGF-beta expression in both the EC and dentate gyrus, whereas LY379268 increased TGF-beta in the EC only. Finally, neuroprotective effects of LY379268 were accompanied by prevention of deficits in spatial reversal learning.. Our data support a neuroprotective role for group II metabotropic glutamate receptor agonists and TGF-beta in alcohol-induced neurodegeneration.

Topics: Amino Acids; Analysis of Variance; Animals; Anxiety; Bridged Bicyclo Compounds, Heterocyclic; Cognition Disorders; Dose-Response Relationship, Drug; Drug Interactions; Ethanol; Fluoresceins; Gene Expression Regulation; Male; Maze Learning; Nerve Degeneration; Organic Chemicals; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate; Reversal Learning; Transforming Growth Factor beta

Spinal and bulbar muscular atrophy (SBMA) is a late-onset lower motor neuron disease caused by the expansion of a trinucleotide CAG repeat, which encodes a polyglutamine tract in androgen receptor (AR). Although it is commonly held that the pathogenic polyglutamine proteins accumulate in neurons and thereby induce transcriptional dysregulation, the downstream molecular events have remained elusive. Here, we examined whether TGF-beta signaling is dysregulated in SBMA. Nuclear translocation of phosphorylated Smad2/3, a key step in TGF-beta signaling, is suppressed in the spinal motor neurons of male transgenic mice carrying the mutant human AR. A similar finding was also observed in the motor neurons, but not in Purkinje cells, of SBMA patients. The pathogenic AR, the causative protein of SBMA, inhibits the transcription of TGF-beta receptor type II (TbetaRII) via abnormal interactions with NF-Y and p300/CBP-associated factor. Furthermore, overexpression of TbetaRII dampens polyglutamine-induced cytotoxicity in a neuroblastoma cell line expressing the pathogenic AR. The present study thus indicates that disruption of TGF-beta due to the transcriptional dysregulation of TbetaRII is associated with polyglutamine-induced motor neuron damage in SBMA.

Topics: Aged; Animals; Humans; Male; Mice; Mice, Transgenic; Middle Aged; Motor Neurons; Muscular Atrophy, Spinal; Muscular Disorders, Atrophic; Nerve Degeneration; Signal Transduction; Transforming Growth Factor beta

Traumatic spinal cord injury (SCI) triggers inflammatory reactions in which various types of cells and cytokines are involved. Several proinflammatory cytokines are up-regulated after SCI and play crucial roles in determining the extent of secondary tissue damage. However, relatively little is known about antiinflammatory cytokines and their roles in spinal cord trauma. Recent studies have shown that an antiinflammatory cytokine, interleukin-4 (IL-4), is expressed and exerts various modulatory effects in CNS inflammation. We found in the present study that IL-4 was highly expressed at 24 hr after contusive SCI in rats and declined thereafter, with concurrent up-regulation of IL-4 receptor subunit IL-4alpha. The majority of IL-4-producing cells were myeloperoxidase-positive neutrophils. Injection of neutralizing antibody against IL-4 into the contused spinal cord did not significantly affect the expression levels of proinflammatory cytokines such as IL-1beta, IL-6, and tumor necrosis factor-alpha or other antiinflammatory cytokines such as IL-10 and transforming growth factor-beta. Instead, attenuation of IL-4 activity led to a marked increase in the extent of ED1-positive macrophage activation along the rostrocaudal extent at 7 days after injury. The enhanced macrophage activation was preceded by an increase in the level of monocyte chemoattractant protein-1 (MCP-1/CCL2). Finally, IL-4 neutralization resulted in more extensive cavitation at 4 weeks after injury. These results suggest that endogenous expression of antiinflammatory cytokine IL-4 regulates the extent of acute macrophage activation and confines the ensuing secondary cavity formation after spinal cord trauma.

Topics: Animals; Blotting, Western; Chemokine CCL2; Contusions; Cytokines; DNA Primers; Female; Image Processing, Computer-Assisted; Immunohistochemistry; Interleukin-4; Macrophage Activation; Nerve Degeneration; Neutrophil Infiltration; Rats; Rats, Sprague-Dawley; Receptors, Interleukin-4; Reverse Transcriptase Polymerase Chain Reaction; Spinal Cord Injuries; Transforming Growth Factor beta

Sanfilippo B syndrome (Mucopolysaccharidosis IIIB, MPS IIIB) is a lysosomal storage disease due to mutations in the gene encoding alpha-N-acetylglucosaminidase and is characterized by a severe neurological disorder. Although several studies have been reported for the murine model of the disease, the molecular basis and the sequence of events leading to neurodegeneration remain to be clarified. We previously suggested the possible involvement of the reactive oxygen species in the disease pathogenesis. In the present paper we extended the analysis of oxidative stress by evaluating the production of superoxide ions throughout the CNS and by evaluating the effect of the stress on the cellular macromolecules. These approaches applied to one-month-old, three-month-old and six-month-old mice revealed that oxidative stress is present in the affected cerebrum and cerebellum tissues from one month from birth, and that it results primarily in protein oxidation, both in the cerebrum and cerebellum, with lipid peroxidation, and especially DNA oxidation, appearing milder and restricted essentially to the cerebellum. We also identified additional genes possibly associated with the neuropathology of MPS IIIB disease. Real time RT-PCR analysis revealed an altered expression of the Sod1, Ret, Bmp4, Tgfb, Gzmb and Prf1 genes. Since Gzmb and Prf1 are proteins secreted by NK/cytotoxic T-cells, these data suggest the involvement of cytotoxic cells in the neuronal pathogenesis. Extending our previous study, findings reported in the present paper show that oxidative stress and all the analyzed stress-related pathological changes occur very early in the disease course, most likely before one month of age.

Topics: Aging; Animals; Bone Morphogenetic Protein 4; Brain; DNA; Granzymes; Lipid Peroxidation; Mice; Mucopolysaccharidosis III; NADP; Nerve Degeneration; Oxidation-Reduction; Oxidative Stress; Perforin; Pore Forming Cytotoxic Proteins; Proto-Oncogene Proteins c-ret; Superoxide Dismutase; Superoxide Dismutase-1; Superoxides; Transforming Growth Factor beta

In songbirds, brain injury upregulates glial aromatase. The resulting local estrogen synthesis mitigates apoptosis and enhances cytogenesis by poorly understood mechanisms. Bone morphogenetic proteins (BMPs), long studied for their role in neural development, are also neuroprotective and cytogenic in the adult brain. BMPs remain uncharacterized in songbirds, as do the mechanisms regulating their post-injury expression. We first established the expression of BMPs 2, 4, 6, and 7 in the adult zebra finch brain using RT-PCR. Next, we determined the effect of neural insult on BMP expression, by comparing BMP transcripts between injured and uninjured telencephalic hemispheres using semi-quantitative PCR. The expression of BMPs 2 and 4, but not 6 and 7, increased 24 h post-injury. To determine the influence of aromatase on BMP expression, we compared BMP expression following delivery of the aromatase inhibitor Fadrozole or vehicle into contralateral hemispheres. Fadrozole decreased BMP2, but not BMP4, expression, suggesting that aromatization may induce BMP2 expression following injury. Since BMPs are gliogenic and neurotrophic, future studies will test if the neuroprotective and cytogenic effects of aromatase upregulation are mediated by BMP2. Songbirds may be excellent models towards understanding the role of local estrogen synthesis and its downstream mechanisms on neuroprotection and repair.

Topics: Animals; Apoptosis; Aromatase; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Brain; Brain Injuries; Cell Survival; Cytoprotection; Disease Models, Animal; Enzyme Inhibitors; Estrogens; Female; Finches; Gliosis; Male; Nerve Degeneration; Nerve Regeneration; Neuroglia; Recovery of Function; Species Specificity; Transforming Growth Factor beta; Up-Regulation

We investigated the effects of bone morphogenetic protein-2 (BMP-2) and some other BMPs on regeneration of peripheral motor nerves in vivo. The facial nerves of 24 New Zealand rabbits were crushed to examine a series of retrograde changes in the facial nuclei and axons, in what has been called the "axon reaction". The facial nerves of the experimental group were treated with epineurial coaptation and BMP-2 after the injury. Nerves not treated with BMP-2 were regarded as controls. The expression of BMP-2 was investigated by in situ hybridisation in the neurons of facial nuclei. The electrophysiology, image analysis and transmission electron microscopy were used to evaluate the level of the recovery of facial nerves. The results showed that the axons in the experimental group were thicker and denser than those in the control group four weeks later. The expression of BMP-2 in the neurons of facial nuclei increased after injury. The electron microscopic observations showed that the axons' degeneration in the experimental group was less than that in the control group. Despite the morphological difference between the two groups, there was no apparent difference between them in nerve conduction velocity. These findings suggest that BMP-2 might be involved in the regeneration of facial nerves, and might function as a potential neurotrophic factor.

Topics: Animals; Axons; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Brain Stem; Demyelinating Diseases; Electromyography; Facial Nerve Injuries; Image Processing, Computer-Assisted; Lysosomes; Microscopy, Electron, Transmission; Mitochondria; Motor Neurons; Myelin Sheath; Nerve Degeneration; Nerve Growth Factors; Nerve Regeneration; Neural Conduction; Rabbits; Recombinant Proteins; Recovery of Function; Schwann Cells; Transforming Growth Factor beta

The ME7 model of murine prion disease shows an atypical inflammatory response characterized by morphologically activated microglia and an anti-inflammatory cytokine profile with a marked expression of TGFbeta1. The investigation of the role of TGFbeta1 during a time course disease shows that its expression is correlated with (i) the onset of behavioral abnormalities, (ii) increased activated microglia, (iii) thickening of the basement membrane, and (iv) is associated with increased PrP(sc) deposition. Increasing TGFbeta1 using an adenoviral vector has no significant impact on prion-associated behavioral impairments or on neuropathology. In contrast, inhibition of TGFbeta1 activity using an adenovirus expressing decorin induces severe cerebral inflammation, expression of inducible nitric oxide synthase and acute neuronal death in prion-diseased animals only. These data suggest that TGFbeta1 plays a critical role in the downregulation of microglial responses minimizing brain inflammation and thus avoiding exacerbation of brain damage.

Topics: Animals; Behavior, Animal; Blotting, Western; Brain; Cell Death; Chronic Disease; Decorin; Disease Models, Animal; Extracellular Matrix Proteins; Female; Gene Expression; Glucose; Immunohistochemistry; Inflammation; Laminin; Lymphocytes; Mice; Mice, Inbred C57BL; Microglia; Nerve Degeneration; Neurons; Nitric Oxide Synthase Type II; Plasminogen Activator Inhibitor 1; Prion Diseases; Proteoglycans; PrPSc Proteins; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor beta; Transforming Growth Factor beta1

The levels of the soluble (s) CD40:sCD40 ligand (L) dyad, which belongs to the tumor necrosis factor (TNF)-alpha:TNF-alpha-receptor superfamily, are significantly increased in the cerebrospinal fluid (CSF), but not the serum of cobalamin (Cbl)-deficient (Cbl-D) rats. They were normalized or significantly reduced after treatment with Cbl, transforming growth factor-beta1 or S-adenosyl-L-methionine, and the normal myelin ultrastructure of the spinal cord was concomitantly restored. The concomitance of the two beneficial effects of these treatments strongly suggests that the increases in CSF sCD40:sCD40L levels may participate in the pathogenesis of purely myelinolytic Cbl-D central neuropathy in the rat. In keeping with this, an anti-CD40 treatment prevented myelin lesions.

Topics: Animals; CD40 Antigens; CD40 Ligand; Gastrectomy; Male; Nerve Degeneration; Rats; Rats, Sprague-Dawley; S-Adenosylmethionine; Spinal Cord; Transforming Growth Factor beta; Transforming Growth Factor beta1; Vitamin B 12 Deficiency

In the central nervous system, basement membrane (BM) constituents are predominantly associated with the vasculature. However, under inflammatory conditions, the expression of BM components may alter. Here, we investigated the distribution of several BM components, including laminin, collagen type IV and heparan sulfate proteoglycans in various multiple sclerosis (MS) lesions. We observed irregular and discontinuous BMs in active lesions. Throughout active MS lesions, we found dense networks of BM proteins, which were surprisingly not associated with the cerebrovasculature. These striking parenchymal networks were not observed in chronic inactive MS lesions and brains of non-neurological controls. In addition, we studied the distribution of transforming growth factor-beta1 (TGF-beta1), since it is known as a major modulator of ECM production. Leukocytes, in particular CD68-positive macrophages, expressed high levels of TGF-beta1 and were located in close proximity to parenchymal BM deposits in the MS lesions. We postulate that these BM networks may play a role in the further recruitment of inflammatory cells and form a barrier for axonal regeneration.

Topics: Adult; Aged; Basement Membrane; Brain; Collagen Type IV; Female; Heparan Sulfate Proteoglycans; Humans; Immunohistochemistry; Laminin; Leukocytes; Male; Middle Aged; Multiple Sclerosis; Nerve Degeneration; Reference Values; Saccharomyces cerevisiae Proteins; Tissue Distribution; Transforming Growth Factor beta; Trehalase

Alzheimer's disease (AD) is characterized by progressive neurodegeneration and cerebral accumulation of the beta-amyloid peptide (Abeta), but it is unknown what makes neurons susceptible to degeneration. We report that the TGF-beta type II receptor (TbetaRII) is mainly expressed by neurons, and that TbetaRII levels are reduced in human AD brain and correlate with pathological hallmarks of the disease. Reducing neuronal TGF-beta signaling in mice resulted in age-dependent neurodegeneration and promoted Abeta accumulation and dendritic loss in a mouse model of AD. In cultured cells, reduced TGF-beta signaling caused neuronal degeneration and resulted in increased levels of secreted Abeta and beta-secretase-cleaved soluble amyloid precursor protein. These results show that reduced neuronal TGF-beta signaling increases age-dependent neurodegeneration and AD-like disease in vivo. Increasing neuronal TGF-beta signaling may thus reduce neurodegeneration and be beneficial in AD.

Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cells, Cultured; Dendrites; Gliosis; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nerve Degeneration; Neuroblastoma; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta

Intraneocortical injection of ibotenate, a glutamate analog, in newborn mice produces damage mimicking lesions observed in human infants with cerebral palsy. Previous research using this model has demonstrated that pretreatment with IL-9, a Th2 cytokine, significantly exacerbated excitotoxic brain lesions. The goal of this study is to identify the underlying pathophysiological mechanism of lesion formation. Pretreatment with TGF-beta1 produced the same effects as IL-9 on ibotenate-induced lesions. IL-9 effects were abolished when a specific TGF-beta1 neutralizing antibody is administered at the same time. Real-time PCR, Western blot, and immunohistochemistry showed that pretreatment with IL-9 increased TGF-beta1 neocortical expression. In vitro studies using real-time PCR and immunocytochemistry demonstrated that neurons were a major contributor in IL-9-induced increase of TGF-beta1. In c-Kit mast cell-deficient mice, TGF-beta1 failed to exacerbate excitotoxic brain lesions, suggesting a key role of mast cells in TGF-beta1 effects. A specific inhibitor of mast cell degranulation and histamine receptor blockers abrogated TGF-beta1 effects on excitotoxic lesions, providing further evidence of mast cell involvement and the role of mast cell-derived histamine. Finally, in vitro studies using a mast cell line showed that TGF-beta1 increased histamine in the supernatant. In aggregate, these data support the notion that neuronal TGF-beta1 plays a key role in the IL-9/mast cell interaction, which leads to an exacerbation of neonatal excitotoxic damage through an increased extracellular histamine concentration. The identification of this pathway, if confirmed in human neonates, might have important implications for understanding and preventing cerebral palsy.

Topics: Animals; Animals, Newborn; Antibodies; Brain; Cell Line; Cerebral Palsy; Disease Models, Animal; Female; Histamine; Histamine Antagonists; Interleukin-9; Male; Mast Cells; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurons; Neurotoxins; Receptors, Histamine; Transforming Growth Factor beta; Transforming Growth Factor beta1

Various chronic neurological diseases are associated with increased expression of transforming growth factor-beta1 (TGF-beta1) in the brain. TGF-beta1 has both neuroprotective and neurodegenerative functions, depending on conditions such as duration and the local and temporal pattern of its expression. Previous transgenic approaches did not enable control for these dynamic aspects. To overcome these limitations, we established a transgenic mouse model with inducible neuron-specific expression of TGF-beta1 based on the tetracycline-regulated gene expression system. TGF-beta1 expression was restricted to the brain where it was particularly pronounced in the neocortex, hippocampus and striatum. Transgene expression was highly sensitive to the presence of doxycycline and completely silenced within 6 days after doxycycline application. After long-term expression, perivascular thioflavin-positive depositions, formed by amyloid fibrils, developed. These depositions persisted even after prolonged silencing of the transgene, indicating an irreversible process. Similarly, strong perivascular apolipoprotein E (ApoE) depositions were found after TGF-beta1 expression and these remained despite TGF-beta1 removal. These in vivo observations suggests that the continuous presence of TGF-beta1 as initial trigger is not necessary for the persistence and development of chronic lesions. Neuroprotective effects were observed after short-term expression of TGF-beta1. Death of striatal neurons induced by 3-nitropropionic acid was markedly reduced after induced TGF-beta1 expression.

Topics: Animals; Anti-Bacterial Agents; Apolipoproteins E; Benzothiazoles; Brain; Doxycycline; Gene Expression Regulation; Gene Silencing; Mice; Mice, Transgenic; Molecular Biology; Nerve Degeneration; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Neurotoxins; Nitro Compounds; Plaque, Amyloid; Propionates; Thiazoles; Transfection; Transforming Growth Factor beta; Transforming Growth Factor beta1; Transgenes

Interferon (IFN)-gamma, the main cytokine responsible for immunological defense against Toxoplasma gondii, is essential in all infected tissues, including the central nervous system. However, IFN-gamma-activated microglia may cause tissue injury through production of toxic metabolites such as nitric oxide (NO), a potent inducer of central nervous system pathologies related to inflammatory neuronal disturbances. Despite potential NO toxicity, neurodegeneration is not commonly found during chronic T. gondii infection. In this study, we describe decreased NO production by IFN-gamma-activated microglial cells infected by T. gondii. This effect involved strong inhibition of iNOS expression in IFN-gamma-activated, infected microglia but not in uninfected neighboring cells. The inhibition of NO production and iNOS expression were parallel with recovery of neurite outgrowth when neurons were co-cultured with T. gondii-infected, IFN-gamma-activated microglia. In the presence of transforming growth factor (TGF)-beta1-neutralizing antibodies, the beneficial effect of the parasite on neurons was abrogated, and NO production reverted to levels similar to IFN-gamma-activated uninfected co-cultures. In addition, we observed Smad-2 nuclear translocation, a hallmark of TGF-beta1 downstream signaling, in infected microglial cultures, emphasizing an autocrine effect restricted to infected cells. Together, these data may explain a neuropreservation pattern observed during immunocompetent host infection that is dependent on T. gondii-triggered TGF-beta1 secretion by infected microglia.

Topics: Animals; Animals, Newborn; Antibodies; Cells, Cultured; Coculture Techniques; Fluorescein-5-isothiocyanate; Fluorescent Antibody Technique, Indirect; Fluorescent Dyes; Glycoproteins; Immunohistochemistry; Interferon-gamma; Interleukin-10; Mice; Mice, Inbred BALB C; Microglia; Nerve Degeneration; Neurites; Neurons; Neutralization Tests; Toxoplasma; Transforming Growth Factor beta; Transforming Growth Factor beta1

We have used adult rat peripheral nerve avulsion models to evaluate the effects of neuroprotective molecules on motoneuron degeneration. The right facial nerves of adult Fischer 344 male rats were avulsed and adenoviral vectors encoding glial cell line-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), transforming growth factor-beta2 (TGFbeta2), and growth inhibitory factor (GIF) were injected into the facial canal. The treatment with the vectors significantly prevented the loss of lesioned facial motoneurons, improved choline acetyltransferase (ChAT) immunoreactivity and suppressed the induction of nitric oxide synthase activity in these neurons. In separate experiments, animals were orally administered a solution of a neuroprotective compound T-588 after avulsion. Both free oral administration and oral tube administration of T-588 improved the survival of injured motoneurons and ameliorated their ChAT immunoreactivity. These results indicate that the gene transfer of GDNF, BDNF, TGFbeta2, and GIF and oral administration of T-588 may prevent the degeneration of motoneurons in adult humans with motoneuron injury and motor neuron diseases.

Topics: Adenoviridae; Animals; Brain-Derived Neurotrophic Factor; Diethylamines; Disease Models, Animal; Facial Nerve Injuries; Gene Transfer Techniques; Genetic Vectors; Glial Cell Line-Derived Neurotrophic Factor; Male; Metallothionein 3; Motor Neuron Disease; Motor Neurons; Nerve Degeneration; Nerve Tissue Proteins; Neuroprotective Agents; Peripheral Nerve Injuries; Peripheral Nerves; Rats; Thiophenes; Transforming Growth Factor beta

There is increasing evidence that soluble amyloid-beta peptide (Abeta) uptake into neurons is an early event in the pathogenesis of Alzheimer's disease (AD). Identification of the early events leading to neuronal dysfunction is key to developing therapeutic strategies, but relative roles of receptors and factors modulating uptake are poorly understood. Studies have shown that transforming growth factor beta (TGFbeta), particularly TGFbeta2, can influence the targeting of Abeta to cells in vitro. TGFbeta2 can target Abeta to neurons in organotypic hippocampal slice cultures (OHSC). We examine a specific mechanism for TGFbeta2-mediated targeting of Abeta to neurons. The receptor-associated protein (RAP), a low-density lipoprotein receptor-related protein (LRP) antagonist, can attenuate the cellular targeting of Abeta both in vitro and in vivo and prevent Abeta/TGFbeta2-induced memory retention deficits. Using both in vitro and in vivo methods, we identify LRP as playing a role in TGFbeta2-mediated Abeta uptake, neurodegeneration, and spatial memory impairment.

Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Hippocampus; In Vitro Techniques; LDL-Receptor Related Protein-Associated Protein; Low Density Lipoprotein Receptor-Related Protein-1; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Nerve Degeneration; Neurons; Protein Transport; Transforming Growth Factor beta; Transforming Growth Factor beta2

TGF-beta is a multifunctional regulatory protein with important effects on cell proliferation and differentiation, immune reactivity and extracellular matrix (ECM). During peripheral regeneration it can have growth promoting effects for axonal sprouting, but on the other hand, it may be involved in epineurial scarring and neuroma formation. We studied the expression of TGF-beta1 mRNA in the rat peripheral nerve with real time-PCR at 1, 3, 5, 7, 14, 21, 28, 35, and 42 days after transection. The sciatic nerve was sutured after transection to prevent axonal regeneration. Samples from both proximal and distal stumps were collected. To distinguish the possible different expression in the endo- and epineurium these two compartments were studied separately. The most significant finding was observed in the epineurium of the proximal stump 35 days after the operation. The expression of TGF-beta1 mRNA was over 700 times higher than that found in the non-operated controls. At the same time the expression of TGF-beta1 mRNA in the endoneurium was only twice as high as the values measured from the non-operated controls. Distally the TGF-beta1 mRNA expression in the endoneurium reached its peak after 2 weeks, and at weeks 3-6, the expression was two to four times higher than in the controls. This study supports the concept that TGF-beta1 can affect epineurial scarring.

Topics: Animals; Axotomy; Male; Nerve Degeneration; Nerve Regeneration; Peripheral Nerves; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sciatic Nerve; Transforming Growth Factor beta; Transforming Growth Factor beta1

Neurodegenerative diseases are becoming an increasing social and economical burden as our population ages; but current knowledge of the processes leading to these diseases is still limited, and no effective treatments are available. Neurodegeneration in Alzheimer's disease (AD) is the most common cause of dementia and afflicts an estimated 4 million people in this country alone. Because accumulation of beta-amyloid (Abeta) peptide appears central to AD pathogenesis, large efforts have been directed at understanding and interfering with Abeta production or aggregation. These efforts have largely identified the processes resulting in Abeta production from the larger amyloid precursor protein (APP) and have revealed that Abeta peptide is also produced at low levels in the healthy brain. Interestingly, Abeta production is rapidly increased after neuronal injury, and traumatic brain injury is a known risk factor for AD and Parkinson's disease. In contrast, brain injury in young individuals does not seem to result in AD, and brain injury in animal models can promote Abeta clearance. This suggests that certain factors associated with injury might be able to reduce the accumulation of Abeta. Accumulation of Abeta peptide might be reduced either directly by stimulating phagocytes or other Abeta-degrading processes, or indirectly, by reducing neuronal injury and thus lowering the production of Abeta peptide. Directing the brain's natural mechanisms for clearing Abeta or increasing neuroprotection might therefore be reasonable approaches in interfering with AD pathogenesis.

Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Brain; Cells, Cultured; Down-Regulation; Metabolic Clearance Rate; Mice; Mice, Knockout; Nerve Degeneration; Neurons; Phagocytes; Phagocytosis; Signal Transduction; Transforming Growth Factor beta

Autoimmune CD4(+) T cells can mediate the ability to withstand neurodegenerative conditions. Here we show that the ability to spontaneously manifest a T cell-dependent protective response is restricted by naturally occurring CD4(+)CD25(+) regulatory T cells (Treg); depletion of Treg was beneficial in two mouse strains (C57BL/6J and BALB/c/OLA) differing in their spontaneous T cell-dependent ability to withstand the consequences of optic nerve injury. Passive transfer of exogenous Treg was destructive in BALB/c/OLA mice (which can spontaneously manifest a T cell-dependent protective anti-self response to injury) but beneficial in C57BL/6J mice (which have only limited ability to manifest such a response). This dichotomy was resolved by the finding that, in severe combined immunodeficient mice, a beneficial effect is obtained by passive transfer of either Treg-free CD4(+) T cells (Teff) or Treg alone, indicating that neuroprotection can be achieved by either Treg or Teff in the absence of the other. We attribute these disparate effects of Treg to their differential interaction (in part via IL-10 and transforming growth factor beta) with local innate immune cells (microglia) in the presence and in the absence of effector T cells. Activation of microglia by pro- and antiinflammatory cytokines in suitably controlled amounts might trigger different signal transduction pathways, each of which induces a neuroprotective microglial phenotype. These results suggest that, under neurodegenerative conditions, the effects of Treg, and possibly also of other regulatory T cells, might not be uniform, and that their expression in different individuals might be genetically determined. Therefore, therapeutic intervention based on induction of regulatory T cells might have limitations.

Topics: Animals; Autoantigens; Autoimmunity; CD4-Positive T-Lymphocytes; Interferon-gamma; Interleukin-10; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Mice, SCID; Microglia; Nerve Degeneration; Receptors, Interleukin-2; Species Specificity; Transforming Growth Factor beta; Vaccines

In response to acute damage, Müller glia in the chicken retina have been shown to be a source of proliferating progenitor-like cells. The secreted factors and signaling pathways that regulate this process remain unknown. The purpose of this study was to test whether secreted factors, which are known to promote glial differentiation during development, regulate the ability of Müller glia to proliferate and become retinal progenitors in response to acute damage in mature retina. We made intraocular injections of BMP4, BMP7, EGF, NGF, BDNF, or CNTF before or after a single, toxic dose of N-methyl-d-aspartate (NMDA) and assayed for proliferating progenitor-like cells within the retina. We found that injections of BMP4, BMP7, or CNTF, but not EGF, NGF, or BDNF, before NMDA treatment reduced the number of Müller glia that proliferated and gave rise to progenitor-like cells. CNTF and BMP4, but not NGF or BDNF, greatly reduced the number of cells destroyed by toxin treatment indicating that these factors protect retinal neurons from a severe excitotoxic insult. Injections of CNTF 5 days before NMDA treatment prevented neurotoxin-induced cell death and Müller glial proliferation, while injections of BMP4 had no protective effect. In addition, CNTF injected after NMDA treatment suppressed glial proliferation, while BMP4 did not. We conclude that BMP4 and CNTF, when applied before a toxic insult, act as neuroprotective agents and likely suppress the proliferative response of Müller glia to retinal damage by attenuating the retinal damage; protecting bipolar and amacrine neurons from NMDA-induced cell death. When applied after a toxic insult, CNTF suppressed glial proliferation independent of levels of retinal damage.

Topics: Animals; Bone Morphogenetic Protein 4; Bone Morphogenetic Protein 7; Bone Morphogenetic Proteins; Cell Death; Cell Proliferation; Chick Embryo; Cicatrix; Ciliary Neurotrophic Factor; Gliosis; N-Methylaspartate; Nerve Degeneration; Nerve Growth Factors; Neuroglia; Neuroprotective Agents; Neurotoxins; Retina; Retinal Diseases; Transforming Growth Factor beta

It is likely that the environment within the injured spinal cord influences the capacity of fetal spinal cord transplants to support axonal growth. We have recently demonstrated that fetal spinal cord transplants and neurotrophin administration support axonal regeneration after spinal cord transection, and that the distance and amount of axonal growth is greater when these treatments are delayed by several weeks after injury. In this study, we sought to determine whether differences in inflammatory mediators exist between the acutely injured spinal cord and the spinal cord after a second injury and re-section, which could provide a more favorable environment for the axonal re-growth. The results of this study show a more rapid induction of transforming growth factor (TGF) beta1 mRNA expression in the re-injured spinal cord than the acutely injured spinal cord and an attenuation of proinflammatory cytokine mRNA expression. Furthermore, there was a rapid recruitment of activated microglia/macrophages in the degenerating white matter rostral and caudal to the injury but fewer within the lesion site itself. These findings suggest that the augmentation of TGFbeta-1 gene expression and the attenuation of pro-inflammatory cytokine gene expression combined with an altered distribution of activated microglia/macrophages in the re-injured spinal cord might create a more favorable milieu for transplants and axonal regrowth as compared to the acutely injured spinal cord.

Topics: Animals; Axons; Cytokines; Female; Gene Expression Regulation; Immunohistochemistry; Macrophages; Microglia; Nerve Degeneration; Nerve Regeneration; Nuclease Protection Assays; Rats; Rats, Sprague-Dawley; RNA, Messenger; Spinal Cord Injuries; Transforming Growth Factor beta

The capacity of Schwann cells (SCs) in the peripheral nervous system to support axonal regeneration, in contrast to the oligodendrocytes in the central nervous system, has led to the misconception that peripheral nerve regeneration always restores function. Here, we consider how prolonged periods of time that injured neurons remain without targets during axonal regeneration (chronic axotomy) and that SCs in the distal nerve stumps remain chronically denervated (chronic denervation) progressively reduce the number of motoneurons that regenerate their axons. We demonstrate the effectiveness of low-dose, brain-derived neurotrophic and glial-derived neurotrophic factors to counteract the effects of chronic axotomy in promoting axonal regeneration. High-dose brain-derived neurotrophic factor (BDNF) on the other hand, acting through the p75 receptor, inhibits axonal regeneration and may be a factor in stopping regenerating axons from forming neuromuscular connections in skeletal muscle. The immunophilin, FK506, is also effective in promoting axonal regeneration after chronic axotomy. Chronic denervation of SCs (>1 month) severely deters axonal regeneration, although the few motor axons that do regenerate to reinnervate muscles become myelinated and form enlarged motor units in the reinnervated muscles. We found that in vitro incubation of chronically denervated SCs with transforming growth factor-beta re-established their growth-supportive phenotype in vivo, consistent with the idea that the interaction between invading macrophages and denervated SCs during Wallerian degeneration is essential to sustain axonal regeneration by promoting the growth-supportive SC phenotype. Finally, we consider the effectiveness of a brief period of 20 Hz electrical stimulation in promoting the regeneration of axons across the surgical gap after nerve repair.

Topics: Animals; Autonomic Denervation; Axons; Axotomy; Brain-Derived Neurotrophic Factor; Cell Count; Colforsin; Dextrans; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Electric Stimulation; Evoked Potentials, Motor; Humans; In Vitro Techniques; Mice; Mice, Knockout; Motor Neurons; Muscle Contraction; Nerve Degeneration; Nerve Growth Factors; Nerve Regeneration; Peripheral Nerve Injuries; Peripheral Nerves; Rats; Receptor, Nerve Growth Factor; Receptor, trkB; Receptors, Nerve Growth Factor; Recovery of Function; Rhodamines; Schwann Cells; Tacrolimus; Time Factors; Transforming Growth Factor beta

Following peripheral nerve transection, CX3CR1 and TGF-beta1 are increased in a time-dependent manner within the injured facial motor nucleus. To explore the relationship between TGF-beta1 and CX3CR1 in the CNS, the effects of TGF-beta1 on CX3CR1 mRNA, protein and fractalkine-dependent stimulation of signal transduction cascades in primary cultures of rat microglia were examined. TGF-beta1 increased steady state levels of CX3CR1 mRNA, 125I-fractalkine binding sites and blunted fractalkine-stimulated ERK1/2 phosphorylation. The half-life of CX3CR1 mRNA was unaltered by TGF-beta1 and two potential Smad binding elements (SBEs) were identified in the rat CX3CR1 promoter. TGF-beta1 may shift fractalkine-dependent signaling away from activation of ERK1/2 towards other pathways and/or may provide a mechanism for microglia to more strongly adhere to neurons.

Topics: Animals; Animals, Newborn; Cells, Cultured; Chemokine CX3CL1; Chemokines, CX3C; Dose-Response Relationship, Drug; Gene Expression Regulation; Membrane Proteins; Microglia; Mitogen-Activated Protein Kinases; Nerve Degeneration; Rats; Rats, Sprague-Dawley; Receptors, Interleukin-8A; RNA, Messenger; Signal Transduction; Time Factors; Transcription, Genetic; Transforming Growth Factor beta; Transforming Growth Factor beta1; Up-Regulation

The intravenous injection of the serine protease, tissue-type plasminogen activator (t-PA), has shown to benefit stroke patients by promoting early reperfusion. However, it has recently been suggested that t-PA activity, in the cerebral parenchyma, may also potentiate excitotoxic neuronal death. The present study has dealt with the role of the t-PA inhibitor, PAI-1, in the neuroprotective activity of the cytokine TGF-beta1 and focused on the transduction pathway involved in this effect. We demonstrated that PAI-1, produced by astrocytes, mediates the neuroprotective activity of TGF-beta 1 against N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity. This t-PA inhibitor, PAI-1, protected neurons against NMDA-induced neuronal death by modulating the NMDA-evoked calcium influx. Finally, we showed that the activation of the Smad3-dependent transduction pathway mediates the TGF-beta-induced up-regulation of PAI-1 and subsequent neuroprotection. Overall, this study underlines the critical role of the t-PA/PAI-1 axis in the regulation of glutamatergic neurotransmission.

Topics: Animals; Animals, Newborn; Astrocytes; Brain; Calcium Signaling; Cells, Cultured; Coculture Techniques; DNA-Binding Proteins; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Fetus; Mice; N-Methylaspartate; Nerve Degeneration; Neurons; Neuroprotective Agents; Neurotoxins; Plasminogen Activator Inhibitor 1; Recombinant Fusion Proteins; Smad3 Protein; Stroke; Tissue Plasminogen Activator; Trans-Activators; Transforming Growth Factor beta; Transforming Growth Factor beta1

Acute CNS lesions lead to neuronal injury and a parallel glial activation that is accompanied by the release of neurotoxic substances. The extent of the original neuronal damage can therefore be potentiated in a process called secondary damage. As astrocytes are known to secrete immunomodulatory and neuroprotective substances, we investigated whether astrocytic factors can attenuate the amount of neuronal injury as well as the degree of microglial activation in a model of excitotoxic neurodegeneration. Treatment of organotypic hippocampal slice cultures with N-methyl-D-aspartate (NMDA) resulted in a reproducible loss of viable granule cells, partial destruction of the regular hippocampal cytoarchitecture and a concomitant accumulation of amoeboid microglial cells at sites of neuronal damage. Astrocyte-conditioned media reduced the amount of NMDA-induced neuronal injury by 45.3%, diminished the degree of microglial activation and resulted in an improved preservation of the hippocampal cytoarchitecture. Transforming growth factor (TGF)-beta failed to act as a neuroprotectant and even enhanced the amount of neuronal injury by 52.5%. Direct effects of astrocytic factors on isolated microglial cells consisted of increased microglial ramification and down-regulated expression of intercellular adhesion molecule-1, whereas incubation with TGF-beta had no such effects. In summary, our findings show that hitherto unidentified astrocyte-derived factors that are probably not identical with TGF-beta can substantially enhance neuronal survival, either by eliciting direct neuroprotective effects or by modulating the microglial response to neuronal injury.

Topics: Animals; Astrocytes; Brain Injuries; Cell Communication; Cell Death; Cell Size; Cells, Cultured; Culture Media, Conditioned; Dentate Gyrus; Disease Models, Animal; Down-Regulation; Excitatory Amino Acid Agonists; Fluorescein-5-isothiocyanate; Gliosis; Growth Substances; Hippocampus; Lectins; Microglia; Microscopy, Confocal; N-Methylaspartate; Nerve Degeneration; Neurons; Neuroprotective Agents; Neurotoxins; Rats; Rats, Wistar; Transforming Growth Factor beta

A number of cytokines contribute to acute experimental neurodegeneration. The cytokine response can have detrimental or beneficial effects depending on the temporal profile and balance between pro- and anti-inflammatory molecules. Our recent data suggest that the pro-inflammatory cytokine interleukin-1beta (IL-1beta) acts at specific sites (e.g., the striatum) in the rat brain to cause distant cortical injury, when co-administered with the potent excitotoxin alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (S-AMPA). The objective of the present study was to investigate changes in the expression of several cytokines simultaneously in the rat striatum and cortex after intrastriatal administration of vehicle, S-AMPA or human recombinant (hr) IL-1beta alone or S-AMPA co-injected with hrIL-1beta using reverse transcription-polymerase chain reaction (RT-PCR; Taqman fluorogenic probes) and enzyme-linked immunosorbent assay (ELISA). Injection of S-AMPA alone increased IL-6 mRNA expression in the ipsilateral striatum after 8 h, whilst striatal injection of IL-1beta alone increased local IL-1beta and IL-1ra mRNAs. The levels of mRNA encoding IL-1alpha, IL-1beta, IL-1ra, IL-6, IL-10 and TNFalpha were markedly elevated in the ipsilateral cortex 8 h after co-injection of S-AMPA and hrIL-1beta. Cortical mRNA levels for IL-4, IL-18, TGFbeta and IFNgamma were not significantly different between treatment groups after 2 h or 8 h. A similar pattern of change in the levels of IL-1alpha and IL-6 protein was observed 8 h after treatment. These data demonstrate selective increases in the expression of cytokines in areas of remote cell death in response to administration of hrIL-1beta and S-AMPA. Such cytokines may be involved in the ensuing damage, and further clarification of their actions could aid future therapeutic strategies for several acute neurodegenerative disorders.

Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Apoptosis; Cerebral Cortex; Corpus Striatum; Cytokines; DNA, Complementary; Excitatory Amino Acid Agonists; Gene Expression Regulation; Humans; Interleukin-1; Interleukins; Male; Nerve Degeneration; Nerve Tissue Proteins; Rats; Rats, Sprague-Dawley; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha

Using reverse transcription polymerase chain reaction (RT-PCR), we have studied the temporal expression of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), transforming growth factor-beta 1 (TGF-beta 1), and tumor necrosis factor-alpha (TNF-alpha) mRNAs in three axotomy paradigms with distinct functional outcomes. Axotomy of adult rat facial motoneurons results in neuronal regeneration, axotomy of neonatal facial motoneurons results in neuronal apoptosis, and axotomy of rubrospinal neurons results in neuronal atrophy. Our RT-PCR findings show that a significant and sustained upregulation of IL-6 mRNA is associated uniquely with the regeneration of adult facial motoneurons. Histochemical studies using IL-6 immunohistochemistry show intense IL-6 immunoreactivity in axotomized adult facial motoneurons. Assessment of reactive glial changes with astroglial and microglial markers reveals that the reactive gliosis following adult facial nerve axotomy is more intense than that observed in either of the other two paradigms. Exposure of cultured microglial cells to IL-6 stimulates microglial proliferation in a dose-dependent manner. Cultured microglia also show expression of IL-6 receptor mRNA, as determined by RT-PCR. Our findings support the idea that reactive gliosis is required for neuron regeneration to occur, and more specifically, they suggest that neuron-derived IL-6 serves as a signalling molecule that induces microglial proliferation during motoneuron regeneration.

Topics: Age Factors; Animals; Axotomy; Cell Communication; Cell Division; Facial Nerve; Female; Gene Expression; Gliosis; Interleukin-1; Interleukin-6; Lectins; Male; Microglia; Nerve Degeneration; Nerve Regeneration; Neurons; Rats; Rats, Wistar; Receptors, Interleukin-6; RNA, Messenger; Signal Transduction; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha

Cytokines are important intercellular messengers involved in neuron-glia interactions and in the microglial-astroglial crosstalk, modulating the glial response to brain injury and the lesion outcome. In this study, excitotoxic lesions were induced by the injection of N-methyl-D-aspartate in postnatal day 9 rats, and the cytokines interleukin-1 beta (IL-1beta), interleukin-6 (IL-6), tumour necrosis factor alpha (TNFalpha) and transforming growth factor beta 1 (TGF-beta1) analysed by ELISA and/or immunohistochemistry. Moreover, cytokine-expressing glial cells were identified by means of double labelling with glial fibrillary acidic protein or tomato lectin binding. Our results show that both neurons and glia were capable of cytokine expression following different patterns in the excitotoxically damaged area vs. the nondegenerating surrounding grey matter (SGM). Excitotoxically damaged neurons showed upregulation of IL-6 and downregulation of TNFalpha and TGF-beta1 before they degenerated. Moreover, in the SGM, an increased expression of neuronal IL-6, TNFalpha and TGF-beta1 was observed. A subpopulation of microglial cells, located in the SGM and showing IL-1beta and TNFalpha expression, were the earliest glial cells producing cytokines, at 2-10 h postinjection. Later on, cytokine-positive glial cells were found within the excitotoxically damaged area and the adjacent white matter: some reactive astrocytes expressed TNFalpha and IL-6, and microglia/macrophages showed mild IL-1beta and TGF-beta1. Finally, the expression of all cytokines was observed in the glial scar. As discussed, this pattern of cytokine production suggests their implication in the evolution of excitotoxic neuronal damage and the associated glial response.

Topics: Age Factors; Animals; Animals, Newborn; Astrocytes; Brain Injuries; Cytokines; Gene Expression Regulation, Developmental; Interleukin-1; Interleukin-6; Microglia; N-Methylaspartate; Neocortex; Nerve Degeneration; Neurons; Rats; Rats, Long-Evans; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha

In this study we have examined whether the slower rate of CNS remyelination that occurs with age is associated with a change in growth factor expression patterns, an association that would provide further support for a causal relationship between growth factors and remyelination. Using quantitative in situ hybridization we have shown that there are differences in IGF-I, TGF-beta 1, and PDGF-A mRNA expression during remyelination of lysolecithin-induced demyelination in the spinal cord of young adult and old adult rats. IGF-I and TGF-beta1 mRNA expression in old rats had a delayed and lower peak expression compared to young rats. The initial increase in PDGF-A mRNA expression was delayed in old rats compared to young rats, but after 5 days both age groups had similar patterns of expression, as was the expression pattern of FGF-2 mRNA at all survival times. In neither age group were increases in CNTF, NT-3, or GGF-2 mRNA expression detected. An analysis of the macrophage response using oligonucleotide probes for scavenger receptor-B mRNA indicated that differences in the macrophage response in young and old animals was the likely cause of the age related change in IGF-I and TGF-beta 1 mRNA expression patterns. On the basis of these data we suggest a model of remyelination in which PDGF is involved in the initial phase of oligodendrocyte progenitor recruitment, while IGF-I and TGF-beta 1 trigger the differentiation of the recruited cells into myelinating oligodendrocytes.

Topics: Aging; Animals; CD36 Antigens; Female; Fibroblast Growth Factor 2; Gene Expression; Glial Fibrillary Acidic Protein; Growth Substances; In Situ Hybridization; Insulin-Like Growth Factor I; Lysophosphatidylcholines; Membrane Proteins; Molecular Sequence Data; Myelin Sheath; Nerve Degeneration; Nerve Regeneration; Oligonucleotide Probes; Platelet-Derived Growth Factor; Rats; Rats, Sprague-Dawley; Receptors, Immunologic; Receptors, Lipoprotein; Receptors, Scavenger; RNA, Messenger; Scavenger Receptors, Class B; Spinal Cord; Transforming Growth Factor beta; Transforming Growth Factor beta1

In this study, the hippocampal neurotoxicant trimethyltin (TMT) was used to examine possible differential susceptibility associated with the apolipoprotein E genotype. Mice-wild type (C57BL6J), APOE knockout, and APOE4 transgenic-received either saline or TMT (2 mg/kg, ip) at either 21 days or 8 months of age. At both ages, similar mRNA levels were seen in the hippocampus across genotypes for ICAM-1, A20, and MAC-1. GFAP mRNA was higher in the APOE knockouts and APOE4 as compared to wild-type mice. Within 24 h, TMT produced cell death of hippocampal dentate granule neurons and mild astrogliosis in all animals. In 21-day-old mice, TMT exposure significantly increased mRNA levels for ICAM-1 and MIP-1alpha in all genotypes. EB-22, GFAP, TNFalpha, and TGF-beta1 levels were significantly elevated in both wild-type and APOE knockout mice following TMT. At 8 months of age, genotype specific differences were observed. mRNA levels for GFAP, TNFbeta, TNFalpha, and MIP-1alpha were increased in both APOE knockout and APOE4 mice compared to wild-type mice. TMT exposure significantly increased mRNA levels for GFAP and MIP-1alpha in all animals. TNFalpha mRNA levels were increased in wild-type and APOE4 mice while EB22 mRNA levels were increased in both the APOE knockout and APOE4 mice but not wild-type mice. These data suggest an age-dependent effect on both microglia early inflammatory responses to injury associated with the APOE genotype.

Topics: Aging; alpha 1-Antichymotrypsin; Animals; Apolipoprotein E4; Apolipoproteins E; Cell Death; Chemokine CCL3; Chemokine CCL4; Cytokines; Female; Gene Expression; Genotype; Glial Fibrillary Acidic Protein; Hippocampus; Intercellular Adhesion Molecule-1; Lymphotoxin-alpha; Macrophage Inflammatory Proteins; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Knockout; Nerve Degeneration; Ribonucleases; RNA, Messenger; Transforming Growth Factor beta; Transforming Growth Factor beta1; Trimethyltin Compounds; Tumor Necrosis Factor-alpha

Young and old Long-Evans rats respond with fevers of equal magnitude and duration to the brain administration of interleukin-1beta (IL-1beta). Here, we characterized brain regional mRNA expression of cytokine and neuropeptide components in response to the brain administration of IL-1beta. We used specific and highly sensitive RNase protection assays to determine mRNA changes for IL-1beta, IL-1 receptor type I (IL-1RI), IL-1R accessory proteins I and II (IL-1R AcP I and II), IL-1 receptor antagonist (IL-1Ra), transforming growth factor-beta1 (TGF-beta1), glycoprotein 130 (gp 130), leptin receptor (OB-R), neuropeptide Y (NPY) and pro-opiomelanocortin (POMC) in the cerebellum, parieto-frontal cortex, hippocampus, hypothalamus, and midbrain of male young (3-5 months) and old (24-26 months) Long-Evans rats. In both young and old rats, IL-1beta induced a significant up-regulation of cerebellar IL-1Ra, IL-1RI, and TGF-beta1 mRNAs; hippocampal TGF-beta1 mRNA; hypothalamic IL-1beta, IL-1Ra, TGF-beta1, and gp 130 mRNAs; and midbrain IL-1beta and TGF-beta1 mRNAs. There were no age-related differences in any cytokine mRNA levels under basal or IL-1beta-stimulated conditions. Levels of hypothalamic POMC mRNA were different between age groups under basal and stimulated conditions. IL-1R AcP I and leptin receptor did not change in any brain region from either young or old rats, suggesting specificity of transcriptional changes. The data show that old Long-Evans rats are not defective in their capacity to develop an appropriate cytokine response to the brain administration of IL-1beta. The implications of these findings for neuroimmunological-neuroinflammatory and neurotoxic/neurodegenerative processes are discussed.

Topics: Aging; Animals; Brain; Cytokines; Fever; Gene Expression Regulation, Developmental; Injections, Intraventricular; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Male; Nerve Degeneration; Nerve Tissue Proteins; Neuropeptide Y; Neuropeptides; Organ Specificity; Pro-Opiomelanocortin; Rats; Receptors, Cytokine; Receptors, Interleukin-1; RNA, Messenger; Sialoglycoproteins; Transcription, Genetic; Transforming Growth Factor beta

To examine the involvement of transforming growth factor-beta (TGF-beta) in the pathogenesis of prion diseases, immunohistochemical studies on both TGF-beta isoforms (beta 1, beta 2 and beta 3) and TGF-beta receptor type II (TGF-beta RII) were performed on the cerebral neocortices of 20 cases with human prion diseases, three cases with Alzheimer's disease, and five control cases. TGF-beta 2 immunoreactivity was thus detected in most neurons and astrocytes in all observed cases of prion disease. TGF-beta 3 immunoreactivity in the astrocytes and TGF-beta RII in the neurons were also detected in 17 of 20 cases with prion diseases. These immunoreactivities had increased markedly regarding the intensity and the number of positive cells in comparison to the control cases, but they were indistinguishable from those observed in Alzheimer's disease cases. In contrast, the TGF-beta 1 immunostaining did not show any apparent difference. Among the cases with prion diseases, however, no significant correlation was revealed between the immunohistochemical results and the clinical and pathological features. The results showed that TGF-beta isoforms thus appear to be differentially involved in the pathogenesis of prion diseases in a similar manner to that of Alzheimer's disease. Furthermore, two cases of prion disease in which pathological findings were free from astrogliosis and neuronal cell degeneration in the cerebral cortices also showed an increased immunoreactivity for TGF-beta 2. Thus, this result suggests that TGF-beta 2 may be involved in the early stages of neuronal cell degeneration in prion diseases.

Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Astrocytes; Brain Chemistry; Female; Gene Expression; Humans; Isomerism; Male; Middle Aged; Nerve Degeneration; Prion Diseases; Transforming Growth Factor beta

The transforming growth factor-beta (TGF-beta) family consists of three isoforms and is part of a larger family of cytokines regulating differentiation, development, and tissue repair. Previous work from our laboratory has shown that TGF-beta1 can increase amyloid-beta protein (Abeta) immunoreactive (Abetair) plaque-like deposits in rat brain. The aim of the current study was to evaluate all three isoforms of TGF-beta for their ability to affect the deposition and neurotoxicity of Abeta in an organotypic, hippocampal slice culture model of Abeta deposition. Slice cultures were treated with Abeta either with or without one of the TGF-beta isoforms. All three isoforms can increase Abeta accumulation (over Abeta treatment alone) within the slice culture, as determined by ELISA. However, there are striking differences in the pattern of Abetair among the three isoforms of TGF-beta. Isoforms 1 and 3 produced a cellular pattern of Abeta staining that colocalizes with GS lectin staining (microglia). TGF-beta2 produces dramatic Abeta staining of pyramidal neurons in layers CA1-CA2. In addition to cellular Abeta staining, plaque-like deposits are increased by all of the TGF-betas. Although no gross toxicity was observed, morphological neurodegenerative changes were seen in the CA1 region when the slices were treated with Abeta plus TGF-beta2. Our results demonstrate important functional differences among the TGF-beta isoforms in their ability to alter the cellular distribution and degradation of Abeta. These changes may be relevant to the pathology of Alzheimer's disease (AD).

Topics: Amyloid beta-Peptides; Animals; Antibodies; Culture Media, Conditioned; Enzyme-Linked Immunosorbent Assay; Hippocampus; Immunohistochemistry; In Vitro Techniques; Inflammation; Mice; Mice, Inbred ICR; Nerve Degeneration; Protein Isoforms; Time Factors; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha

Post-mitotic, human neurons (hNT cells) which have a phenotype similar to that of terminally differentiated neurons of the central nervous system were generated by treating the NT2/D1 human teratocarcinoma cell line with retinoic acid. Treatment of both hNT and NT2/D1 cells with 10(-5) M beta-amyloid peptide fragment 25-35 (A beta P) for 24 h resulted in a decrease in cell viability as determined by MTT incorporation and Trypan blue exclusion, and also induced an apoptotic morphology in hNT cells. Pre-treatment of cells for 24 h with 10 ng/ml TGF-beta 1 or 2 before addition of A beta P reduced the apoptotic morphology of hNT cells and increased cell viability in hNT cells, but not in NT2/D1 cells. Results of RT-PCR, immunohistochemistry and analysis of receptor cross-linking of [125I]TGF-beta 1 to the cell membrane, all showed that the TGF-beta type II receptor is expressed by hNT cells, but not NT2/D1 cells. These results suggest that TGF-beta can protect human, terminally differentiated, TGF-beta type II receptor-positive neurons from A beta P toxicity. We propose that the increased expression of TGF-beta in brains of patients with Alzheimer's disease may offer some degree of neuroprotection if neurons also express a functional TGF-beta type II receptor.

Topics: Amyloid beta-Peptides; Cell Differentiation; Cell Line; Humans; Nerve Degeneration; Neurons; Neuroprotective Agents; Peptide Fragments; Phenotype; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta; Tretinoin; Tumor Cells, Cultured

Transforming growth factor-beta 1 (TGF-beta 1) has been shown to rescue cultured neurons from excitotoxic and hypoxic cell death and to reduce infarct size after focal cerebral ischemia in mice and rabbits. The present study investigated the effects of TGF-beta 1 in a different pathophysiological setting and the delayed neuronal death of hippocampal pyramidal cells after transient global ischemia in rats, and evaluated the potential mechanisms of the neuroprotective activity of TGF-beta 1.. Transient forebrain ischemia was induced in male adult Wistar rats with bilateral occlusion of both common carotid arteries combined with systemic hypotension for 10 minutes. Seven days after ischemia, brains were perfusion-fixed and stained for histological evaluation. TGF-beta 1 or vehicle was injected intracerebroventricularly (ICV; 0.5, 4, and 50 ng) or intrahippocampally (4 ng) 1 hour before ischemia. For in vitro studies, hippocampal neurons were derived from E17 rat embryos and cultured for 10 to 14 days. Cells were exposed to (1) S-nitrosocysteine (SNOC; 30 mumol/L) to induce nitric oxide-induced oxidative injury and (2) staurosporine (0.03 mumol/L) to induce apoptotic cell death.. Transient forebrain ischemia caused extensive degeneration of CA1 hippocampal pyramidal cells in vehicle-treated control animals. Ischemic injury was not significantly reduced after ICV administration of 0.5 ng TGF-beta 1 (71 +/- 7% damaged neurons versus 84 +/- 3% in vehicle-treated controls: n = 9 and 11, respectively; P = .07, Mann-Whitney U test). Administration of 4 ng TGF-beta 1 reduced the percentage of damaged CA1 pyramidal cells from 71 +/- 10% in controls to 52 +/- 7% in TGF-beta 1-treated animals (n = 11 and 12, respectively; P = .04). TGF-beta 1 (4 ng) also produced significant protection when injected directly into the hippocampal tissue. In contrast, ICV administration of 50 ng TGF-beta 1 failed to show a protective effect in two separate sets of experiments. In vitro, a 24-hour pretreatment of the cultured hippocampal neurons with TGF-beta 1 (0.1 to 10 ng/mL) significantly inhibited both nitric oxide and staurosporine neurotoxicity. Posttreatment with TGF-beta 1 (10 ng/mL) also inhibited staurosporine neurotoxicity but actually potentiated nitric oxide-induced neuronal injury.. We demonstrated that TGF-beta 1 in a surprisingly low dose range has the capacity to reduce injury to CA1 hippocampal neurons caused by transient global ischemia in rats. This protective action could well be associated with the antioxidative and antiapoptotic effects of TGF-beta 1 demonstrated in vitro.

Topics: Animals; Apoptosis; Cell Death; Dose-Response Relationship, Drug; Hippocampus; Injections; Injections, Intraventricular; Ischemic Attack, Transient; Male; Nerve Degeneration; Neurons; Neuroprotective Agents; Nitric Oxide; Oxidation-Reduction; Pyramidal Cells; Rats; Rats, Wistar; Staurosporine; Time Factors; Transforming Growth Factor beta

Neuronal degeneration was induced in cultured rat hippocampal neurons by a 20-min exposure to the glutamatergic agonist, N-methyl-D-aspartate (NMDA; 100 microM), and the neuroprotective activity of a set growth factors and cytokines was compared. During the early stages of degeneration, NMDA induced changes that were characteristic of neuronal necrosis, including swelling and darkening of the neuronal soma and swelling of neurites, leading to the formation of beaded varicosities ('blebs'). These changes were followed by nuclear pyknosis, formation of double-stranded DNA breaks and loss of membrane integrity. Only transforming growth factor-beta 1 (TGF-beta 1; 1-10 ng/ml) and tumor necrosis factor-alpha (TNF-alpha; 30 ng/ml) protected the hippocampal neurons against NMDA neurotoxicity after short-term (60 min) pre-treatments. Interleukin-1 beta (10-100 ng/ml) and fibroblast growth factor-2 (FGF-2; 50 ng/ml) were clearly effective when administered 24 h prior to the NMDA exposure, but not when given 60 min before the insult. Interestingly, the protective effect of interleukin-1 beta was significantly reduced in the presence of a neutralizing antibody to TGF-beta. Of note, short-term pre-treatment with brain-derived neurotrophic factor (BDNF; 5-50 ng/ml) significantly potentiated NMDA-induced neurodegeneration. These experiments demonstrate marked diversity in the actions of growth factors on NMDA-induced neuronal degeneration.

Topics: Animals; Brain-Derived Neurotrophic Factor; Cell Culture Techniques; Epidermal Growth Factor; Excitatory Amino Acid Agonists; Fibroblast Growth Factor 2; Gene Expression; Hippocampus; Humans; Interleukin-1; N-Methylaspartate; Nerve Degeneration; Nerve Growth Factors; Neurons; Rats; Rats, Inbred F344; Transforming Growth Factor alpha; Transforming Growth Factor beta

The degeneration of serotonergic neurons increases the expression of glutamate dehydrogenase (GDH) in hippocampal astrocytes. This process was demonstrated to be independent of the serotonin level. At the same time, upregulation of tumor necrosis factor (TNF) alpha and interleukin (IL)-1 alpha mRNA were observed, whereas levels of transforming growth factor (TGF) beta 1 mRNA remained unchanged. The level of GDH mRNA was increased in primary cultures of hippocampal astrocytes treated with TNF alpha and IL-1 alpha suggesting that these cytokines act on the GDH metabolism. TNF alpha and IL-1 alpha induced an increase in GDH promoter activity in C8S (an astrocytic cell line) transfected with constructs containing 5' flanking genomic sequences of GDH driving the expression of a reporter gene. These observations suggest that cytokines may be signals that upregulate the astrocytic GDH expression in response to the degeneration of serotonergic terminals in the hippocampus.

Topics: Animals; Astrocytes; Cells, Cultured; Glutamate Dehydrogenase; Glutamates; Hippocampus; Interleukin-1; Male; Nerve Degeneration; Rats; Rats, Sprague-Dawley; Serotonin; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Up-Regulation

We have previously shown that the brains of patients with Alzheimer's disease (AD) express transforming growth factor (TGF)-beta 2 in neurofibrillary tangle (NFT)-bearing neurons and reactive astrocytes. The present study was undertaken to determine whether other neurodegenerative diseases were also associated with an alteration of the TGF-beta's. The immunohistochemical expression of TGF-beta 1, -2 and -3 was assessed in the brains of patients with progressive supranuclear palsy (n = 2), amyotrophic lateral sclerosis (n = 3), Lewy body disease (n = 5), Parkinson's disease (n = 1), Shy-Drager syndrome (n = 1), Pick's disease (n = 3), lobar atrophy (n = 1), and corticobasal degeneration (n = 2). Our results were compared to norms for controls (n = 8). We found expression of TGF-beta 2 in both NFT bearing neurons and tangle-bearing glial cells in progressive supranuclear palsy and in neurons with age-related NFT formation. Widespread staining of reactive astrocytes for TGF-beta 2 was observed in all degenerative diseases. TGF-beta 1 and -3 staining was not selectively altered in these diseases. We conclude that induction of TGF-beta 2 may be an intrinsic part of the processes that underlie NFT formation and reactive gliosis in a variety of neurodegenerative diseases.

Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Central Nervous System Diseases; Female; Humans; Male; Middle Aged; Nerve Degeneration; Neuroglia; Neurons; Transforming Growth Factor beta

The transforming growth factor-beta 1 (TGF-beta 1) has been shown to be an injury-related peptide growth factor within the mammalian brain. We tested TGF-beta 1 for its protective effects against neuronal degeneration caused by sodium cyanide (1 mM) or by the excitatory amino acid L-glutamate (1 mM) in vitro and against ischemic injury in vivo caused by permanent occlusion of the left middle cerebral artery in mice. In vitro, TGF-beta 1 (1-30 ng/ml) significantly reduced hypoxic and excitotoxic neuronal damage in a concentration-dependent manner. In vivo, intracerebroventricular administration of TGF-beta 1 (1 microgram/kg) decreased the infarcted area on the mouse brain surface. The present results suggest that TGF-beta 1 is capable of protecting neurons against damage both in vitro and in vivo.

Topics: Animals; Brain Ischemia; Cells, Cultured; Cerebral Cortex; Chick Embryo; Glutamic Acid; Hypoxia; Male; Mice; Mice, Inbred Strains; Nerve Degeneration; Neurons; Neuroprotective Agents; Rats; Rats, Inbred F344; Telencephalon; Transforming Growth Factor beta

The transforming growth factors-beta (TGFs-beta) are multifunctional peptide growth factors that have been localized in neuronal and glial cells of the CNS of mice, rats, and chick embryos. We tested the TGF-beta isoforms 1, 2, and 3 for their protective effects against neuronal degeneration caused by cytotoxic hypoxia or by the excitatory amino acid L-glutamate. A cytotoxic hypoxia was induced in cultured chick embryo telencephalic neurons by adding 1 mM sodium cyanide to the culture medium for a period of 30 min. Treatment with TGF-beta 1 (1-30 ng/ml) led to a statistically significant increase in cell viability, neuronal ATP levels, and protein content of the cultures assessed 72 h after the toxic insult. TGF-beta 3 was able to reduce the cyanide-induced neuronal damage at concentrations of 0.3 and 1 ng/ml, whereas TGF-beta 2 only showed neuroprotective activity at concentrations of 30 and 50 ng/ml. Both pre- and post-treatment with TGF-beta 1 also prevented the degeneration of cultured chick embryo telencephalic neurons that had been exposed to 1 mM L-glutamate in a buffered salt solution for a period of 60 min. Furthermore, TGF-beta 1 (0.3-3 ng/ml), and to a lesser extent TGF-beta 3 (0.1-1 ng/ml), significantly reduced excitotoxic injury of cultured neurons from rat cerebral cortex that had been exposed to serum-free culture medium supplemented with 1 mM L-glutamate. These results demonstrate that the TGFs-beta are able to prevent the degeneration of primary neuronal cultures, which was caused by energy depletion and activation of glutamate receptors, in an isoform-specific manner.

Topics: Animals; Cell Hypoxia; Cells, Cultured; Cerebral Cortex; Chick Embryo; Glutamates; Glutamic Acid; Isomerism; Nerve Degeneration; Neurons; Telencephalon; Transforming Growth Factor beta

This study examined TGF-beta 1 mRNA levels and cellular localization in the F344 rat hippocampus following deafferentation or kainic acid (KA)-induced neurodegeneration. By RNA solution hybridization, TGF-beta 1 transcripts were at low prevalence in intact adult rat hippocampus (0.02 pg/microgram total RNA). Four days after unilateral entorhinal cortex lesioning (ECL), TGF-beta 1 mRNA increased threefold in the ipsilateral hippocampus. This increase was localized to the outer molecular layer of the dentate gyrus, where gliosis, synapse loss, and synaptic reorganization occur. TGF-beta 1 mRNA also increased in the hippocampus after KA-induced limbic seizures, particularly in the areas of the hippocampus undergoing neurodegeneration. Microglia [OX-42 immunoreactive (IR) cells] responded to these two lesions with distinct morphological changes. Combined immunocytochemistry-in situ hybridization showed that TGF-beta 1 mRNA was localized to reactive microglia (OX-42-IR, with blunt processes), but not to resting ramified microglia (OX-42-IR, with numerous fine processes) or to astrocytes (GFAP-IR). After ECL, round macrophage-like cells (OX-42-IR with TGF-beta 1 mRNA) were seen at the wound site. Thus, brain macrophage/microglial cells produce TGF-beta 1 mRNA in the hippocampus in response to deafferentation and neurodegeneration.

Topics: Afferent Pathways; Animals; Glial Fibrillary Acidic Protein; Hippocampus; Kainic Acid; Limbic System; Macrophages; Male; Mesoderm; Nerve Degeneration; Rats; Rats, Inbred F344; RNA, Messenger; Seizures; Temporal Lobe; Transforming Growth Factor beta